scholarly journals Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?

2006 ◽  
Vol 52 (3) ◽  
pp. 345-351 ◽  
Author(s):  
Michael J Duffy
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Primary Treatment ◽  
Serum Markers ◽  
Clinical Value ◽  
Serum Tumor Markers ◽  
Monitoring Therapy ◽  
Monitoring Treatment

Abstract Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. Methods: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. Results: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers is of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of ∼2–9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria. Conclusions: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.

scholarly journals Usefulness of Traditional Serum Biomarkers for Management of Breast Cancer Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Peppino Mirabelli ◽  
Mariarosaria Incoronato
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Serum Markers ◽  
Response To Therapy ◽  
Breast Cancer Patients ◽  
Serum Tumor Markers ◽  
Scientific Organizations ◽  
Positron Emission ◽  
Oncology Practice ◽  
Intense Debate

The measurement of serum tumor markers levels in breast cancer (BC) patients is an economic and noninvasive diagnostic assay frequently requested by clinical oncologists to get information about the presence or absence of disease as well as its evolution. Despite their wide use in clinical practice, there is still an intense debate between scientific organizations about the real usefulness for patient monitoring during followup as well as response to therapy evaluation in case of advanced BC. In this review, we want to highlight the current recommendations published by scientific organizations about the use of “established” BC serum markers (CEA, TPA, TPS, CIFRA-21, CA15-3, and s-HER2) in clinical oncology practice. Moreover, we will focus on recent papers evidencing the usefulness of tumor markers levels measurement as a guide for the prescription and diagnostic integration of molecular imaging exams such as those performed by hybrid 18-fluorofeoxyglucose-positron emission tomography with integrated computed tomography. This technology is nowadays able to detect early cancer lesions undetectable by conventional morphological imaging investigation and most likely responsible for increasing of serum tumor markers levels.

Serum Tumor Markers in Stage I-II Breast Cancer

2016 ◽  
Vol 12 (3) ◽  
pp. 285-289 ◽  
Author(s):  
Renato Tozzoli ◽  
Federica D';Aurizio ◽  
Flavio Falcomer ◽  
Stefano M.M. Basso ◽  
Franco Lumachi
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Stage I ◽  
Serum Tumor Markers

CLINICAL VALUE OF SERUM TUMOR MARKERS IN PATIENTS UNDERGOING BRONCHOSCOPY

1996 ◽  
Vol 3 (3) ◽  
pp. 250
Author(s):  
A Haritou ◽  
G Kolios ◽  
S Loukas ◽  
C Seferiades ◽  
S Constantopoulos
Keyword(s):  
Tumor Markers ◽  
Clinical Value ◽  
Serum Tumor Markers

Diagnosis of Bone and Liver Metastases in Breast Cancer Comparing Tumor Markers and Imaging Techniques

1989 ◽  
Vol 4 (2) ◽  
pp. 103-105 ◽  
Author(s):  
P. Zanco ◽  
G. Rota ◽  
V. Sportiello ◽  
N. Borsato ◽  
G. Ferlin
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Bone Metastases ◽  
Tumor Markers ◽  
Imaging Techniques ◽  
Hepatic Metastases ◽  
Serum Levels ◽  
Serum Markers ◽  
Surgical Removal ◽  
Rule Out

One hundred and forty-seven patients were examined by bone scintigraphy, ultrasonography and scintigraphic scan of the liver, at different times after surgical removal of a breast cancer, to rule out skeletal and hepatic metastases. At the same time as imaging procedures, serum levels of tumor markers (CEA, TPA and CA 15–3) were determined using radioimmunometric methods. One or more markers were elevated in all 13 patients with hepatic metastases; 9 out of 46 patients with bone metastases had all serum markers normal, with a sensitivity of 80%. Combined assay of the markers proved useful, TPA and CA 15–3 showing the best sensitivity in bone metastases, and all three markers in liver metastases.

scholarly journals The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

2019 ◽  
Vol 33 (5) ◽  
Author(s):  
Mingjian Lian ◽  
Cuixia Zhang ◽  
Dongdong Zhang ◽  
Ping Chen ◽  
Huijing Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Pathological Features ◽  
Serum Tumor Markers ◽  
Preoperative Serum

Elevated CA 19-9 Levels in Mature Cystic Teratoma of the Ovary

2009 ◽  
Vol 24 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Min Sun Kyung ◽  
Joong Sub Choi ◽  
Seung Hwa Hong ◽  
Hak Soon Kim
Keyword(s):  
Tumor Markers ◽  
Elevated Serum ◽  
Cystic Teratoma ◽  
Ovarian Torsion ◽  
Mature Cystic Teratoma ◽  
Ca 125 ◽  
Clinical Value ◽  
Blood Samples ◽  
Serum Tumor Markers

The purpose of this study was to evaluate the clinical value of serum tumor markers in patients with ovarian mature cystic teratoma (MCT). We retrospectively evaluated 163 women who underwent surgery for MCT of the ovary between March 2003 and August 2007 and who provided preoperative blood samples for the measurement of CA 19-9 and CA 125. The rates of elevated serum CA 19-9 and CA 125 levels were 31.9% (52/163) and 13.5% (22/163), respectively. The rate of ovarian torsion was 12.9% (21/163). There were significant differences between the elevated CA 19-9 group and the normal CA 19-9 group in the diameters of the tumors and the rates of ovarian torsion. Elevated serum CA 19-9 levels correlated with larger tumor diameters and higher torsion rates. CA 19-9 may be a useful tool for the diagnosis of ovarian MCT. Elevated CA 19-9 levels appear to correlate with larger tumor diameters and higher rates of ovarian torsion.

Sign in / Sign up

Export Citation Format

Share Document